Soft drugs. 12. Design, synthesis, and evaluation of soft bufuralol analogues

Journal of Medicinal Chemistry

Volumn 43, Issue 8, 2000, Pages 1525-1532

  Hwang, Sung Kwan ^a   Juhasz, Attila ^b   Yoon, Sung Hwa ^a   Bodor, Nicholas ^c  

^a Ajou University   (South Korea)

^b UNIVERSITY OF DEBRECEN   (Hungary)

^c UNIVERSITY OF FLORIDA HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUFURALOL; DRUG METABOLITE; ESMOLOL; ESTER; ISOPRENALINE;

ANIMAL EXPERIMENT; ARTICLE; BLOOD PRESSURE; BRADYCARDIA; CONTROLLED STUDY; DRUG EFFECT; DRUG STRUCTURE; DRUG SYNTHESIS; HEART RATE; HYPOTENSION; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; RAT; TACHYCARDIA;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; BLOOD PRESSURE; BUFFERS; DRUG STABILITY; ETHANOLAMINES; HEART RATE; MALE; RATS; RATS, SPRAGUE-DAWLEY; STRUCTURE-ACTIVITY RELATIONSHIP; TACHYCARDIA; WATER;

EID: 0034692180     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9904654     Document Type: Article

References (47)

1. Frishman, W. H. ; Herahman, D. Beta-Adrenergic Blocking Drugs in Cardiac Disorders. In Cardiovascular Drug Therapy, 2nd ed.; Messerli, F. H., Ed.; W. B. Saunders Co.: New York, 1996; pp 465-474.
2. Gerber, J. G.; Nies, A. S. Beta-Adrenergic Blocking Drugs. Annu. Rev. Med. 1985, 36, 145-164.
3. McDevit, D. G. Adrenoceptor Blocking Drugs: Clinical Pharmacology and Therapeutic Use. Drugs 1979, 17, 267-288.
4. Greeblatt, D. J.; Koch-Weser, J. Adverse Reactions to β-Adrenergic Blocking drugs: A Report from Boston Collaborative Drug Surveillance Program. Drugs 1974, 7, 118-129.
5. Brian, G.; Tucker, H. Recent Advances in β-Adrenergic Blocking Agents. Progress in Medicinal Chemistry; Elsevier Science Publishers E.V.: Amsterdam, 1985; Vol. 22, pp 121-164.
6. Evans, D. B.; Fox, R.; Hauck, F. P. β-Adrenergic Receptor Blockers as Therapeutic Agents. Academic Press. Annu. Rep. Med. Chem. 1979, 14, 81-90.
7. Erhardt, P. W.; Woo, C. M.; Gorzynski, R. J.; Anderson, W. G. Ultra-Short-Acting β-Adrenergic Blocking Agent. 1. (Aryloxy)-propanolamines Containing Esters in the Nitrogen Substituent. J. Med. Chem. 1982, 25, 1402-1407.
8. Frishman, W. H.; Shrinivas Murthy, V.; Strom, J. A.; Hershman, D. Ultrashort-Acting Beta-Adrenoceptor Blocking Drug: Esmolol. In Cardiovascular Drug Therapy, 2nd ed.; Messerli, F. H., Ed.; W. B. Saunders Co.: New York, 1996; pp 507-516.
9. Erhardt, P. W.; Woo, C. M.; Anderson, W. G.; Gorczynski, R. J. Ultra-Short-Acting β-Adrenergic Receptor Blocking Agents. 2. (Aryloxy)propanolamines Containing Esters on the Aryl Function. J. Med. Chem. 1982, 25, 1408.
10. Erhardt, P. W. Esmolol. In Chronicles of Drug Discovery; Lednicer, D., Ed.; ACS Books: Washington D.C., 1993; p 191.
11. Bourne, G. R, The Metabolism of β-Adrenoceptor Blocking Drugs. Progress in Drug Metabolism; John Wiley & Sons Ltd.: New York, 1981; pp 77-110.
12. Fothergill, G. A.; Osbond, J. M.; Wickens, J. C. Bufuralol, a New Beta-Adrenoceptor Blocking Agent. Part 1: Synthesis and structure-activity studies in a series of benzofuran-2-ethanolamines. Arzneim.-Forsch. 1977, 27, 978-981.
13. Hamilton, T. C.; Parkes M. W. Bufuralol, a New Beta-Adrenoceptor Blocking Agent in a Series of Benzofuran-2-ethanolamines. Part 2: Pharmacology. Arzneim.-Forsch. 1977, 27, 1410-1417.
14. Johnston, G. D.; Finch, M. B.; Shanks, R. G. Peripheral Vascular Effects of Bufuralol in Hypertensive and Normal Subjects: A Comparison with Propranolol and Pindolol. Eur. J. Clin. Pharmacol. 1986, 30, 649-652.
15. Magometschnigg, D.; Bonelli, J.; Kaik, G.; Rameis, H. Hemodynamic Changes in Hypertensive Patients at Rest and During Physical Exercise Before and After Acute i.v. Administration of Bufuralol-HCl or Propranolol. Int. J. Clin. Pharmacol. Biopharmacol. 1979, 17, 334-340.
16. Magometschnigg, D.; Bonelli, J.; Hitzenberger, G.; Kaik, G.; Korn, A. Decrease of Peripheral Resistance After Acute Intravenous Application of a New Beta-Receptor Blocking Agent, Bufuralol HCl. Int. J. Clin. Pharmacol. 1978, 16, 54-58.
17. Dayer, P.; Balant, L.; Courvoisier, F.; Kupfer, A.; Kubli, A.; Gorgia, A.; Fabre, J. The Genetic Control of Bufuralol Metabolism in Man. Eur. J. Drug Metab. Pharmacokinet. 1982, 7, 73-77.
18. Machin, P. J.; Hurst, D. N.; Osbond, J. M. β-Adrenoceptor Activity of the Stereoisomer of the Bufuralol Alcohol and Ketone Metabolites. J. Med. Chem. 1985, 28, 1648-1651.
19. Weerawarrma, S. A.; Geisshusler, S. M.; Murthy, S. S.; Nelson, W. L. Enantioselective and Diastereoselective Hydroxylation of Bufuralol Absolute Configuration of the 7-(1-Hydroxyethyl)-2-[1-hydroxy-2-(tert-butylamino)ethyl]benzofurans, the Benzylic Hydroxylation Metabolites. J. Med. Chem. 1991, 34, 3091-3097.
20. Francis, R. J.; East, P. B.; Larman, J. Kinetics and Metabolism of (+),(-), and (±)-Bufuralol. Eur. J. Clin. Pharmacol. 1982, 23, 529-533.
21. Eckert, M.; Cocco, G.; Strozzi, C.; Heizmann, P.; Sfrisi, C. Relationship Between Pharmacokinetic and Pharmacodynamic Behaviour of Bufuralol and its Metabolite Ro 3-7410 in Hypertensive Patients. Eur. J. Clin. Pharmacol. 1983, 24, 479-484.
22. Pringle, T. H.; Francis, R. J.; East, P. B.; Shanks, R. G. Pharmacodynamic and Pharmacokinetic studies on Bufuralol in Man. Br. J. Clin. Pharmacol. 1986, 22, 527-534.
23. Dayer, P.; Kronbach, T.; Eichelbaum, M.; Meyer, U. A. Enzymatic Basis of the Debrisoquine/Sparteine-Type Genetic Polymorphism of Drug Oxidation. Characterization of Bufuralol 1′-Hydroxylation in Liver Microsomes of in vivo Phenotyped Carriers of the Genetic Deficiency. Biochem. Pharmacol. 1987, 36, 4145-4152.
24. Dayer, P.; Leemann, T.; Kupfer, A.; Kronbach, T.; Meyer, U. A. Stereo- and Regioselectivity of Hepatic Oxidation in Man -Effect of the Debrisoqume/Sparteine Phenotype on Bufuralol Hydroxylation. Eur. J. Clin. Pharmacol. 1986, 31, 313-318.
25. Guengerich, F. P.; Umbenhauer, D. R.; Churchill, P. F.; Beaune, P. H.; Bocker, R.; Knodell, R. G.; Martin, M. V.; Lloyd, R. S. Polymorphism of Human Cytochrome P-450. Xenobiotica 1987, 17, 311-316.
26. Gut, J.; Gasser, R.; Dayer, P.; Kronbach, T.; Catin, T.; Meyer, U. A. Debrisoquine-Type Polymorphism of Drug Oxidation: Purification from Human Liver of a Cytochrome P-450 Isozyme with Hugh Activity for Bufuralol Hydroxylation. FEBS Lett. 1984, 173, 287-290.
27. Lennard, M. S.; Tucker, G. T.; Woods, H. F. The Polymorphic Oxidation of Beta-Adrenoceptor Antagonists. Clinical Pharmacokinetic Considerations. Clin. Pharmacokinet. 1986, 11, 1-17.
28. Smith, R. L. Polymorphic Metabolism of the Beta-Adrenoceptor Drugs and its Clinical Relevance. Eur. J. Clin. Pharmacol. 1985, 28 (Suppl.), 77-84.
29. Lennard, M. S. Oxidation Phenotype and the Metabolism and Action of Beta-Blockers. Klin. Wochenschr. 1985, 63, 285-292.
30. Dayer, P.; Kubli, A.; Kupfer, A.; Courvoisier, F.; Balant, L.; Fabre, J. Defective Hydroxylation of Bufuralol Associated with Side-Effects of the Drug in Poor Metabolizers. Br. J. Clin. Pharmacol. 1982, 12, 750-751.
31. Bodor, N. Soft Drugs. In Encyclopedia of Human Biology; Dulbecco, R., Ed.; Academic Press Inc.: New York, 1991; pp 101-117.
32. Bodor, N. Novel Approaches to the Design of Safer Drugs: Soft Drugs and Site Specific Chemical Delivery System. In Advances in Drug Research, 13; Testa, B., Ed.: Academic Press: London, 1987; pp 255-331.
33. Bodor, N.; Oshiro, Y.; Loftsaon, T.; Katovich, M.; Caldwell, W. Soft Drugs VI. The Application of the Inactive Metabolite Approach for Design of Soft β-Blocker. Pharm. Res. 1984, 3, 120-124.
34. Bodor, N.; Elkoussi, A. Novel "Soft"β-Blockers as Potential Safe Antiglaucoma Agents. Curr. Eye Res. 1988, 7, 369-374.
35. Bodor, N.; Elkoussi, Kano, M.; Khalifa, M. Soft Drugs 7. Soft β-Blockers for Systemic and Ophthalmic Use. J. Med. Chem. 1988, 28, 1651-1656.
36. Yang, H. S.; Wu, W. M.; Bodor, N. Soft Drugs. XX. Design, Synthesis, and Evaluation of Ultra-Short Acting Beta-blockers. Pharm. Res. 1996, 12, 329-336.
37. Casiraghi, G.; Casnati, G.; Puglia, G.; Sartori, G. I.; Terebghi, G. Selective Reactions between Phenols and Formaldehyde. A Novel Route to Salicylaldehyedes. J. Chem. Soc., Perkin Trans. 1 1980, 1862-1865.
38. Jordan, S.; Markwell, R. E.; Woolcott, B. S. The Synthesis and oxidation of N-Hydroxy-derivatives of the β-Adrenoceptor Antagonists Bufuralol and Toliprolol. J. Chem. Soc. Perkin Trans. I 1978, 928-933.
39. Ireland, R. E.; Thaisrivongs, S.; Dussault, P. H. An Approach to the Total Synthesis of Aplysiatoxin. J. Am. Chem. Soc. 1988, 110, 5768-5779.
40. Jen, T.; Frazee, J. S.; Kaiser, C. Adrenergic Agents. Synthesis and Potential β-Adrenergic Agonist Activity of Some Meta-Substituted p-Hydroxyphenyl ethanolamines Related to Salbutamol. J. Med. Chem. 1977, 20, 1029-1035.
41. Tucker, H. Stereospecific Synthesis of threo- and erythro-1-(Aryloxy)-3-(alkylamino)butan-2-ols. J. Org. Chem. 1979, 44, 2943-2944.
42. Fieser, L.; Fieser M. Reagents for Organic Synthesis; John Wiley and Sons Ltd.: New York, 1967; p 705.
43. Ono, N.; Yamada, T.; Saito, T.; Tanaka, K.; Daji, A. A Convenient Procedure for Esterification of Carboxylic Acids. Bull. Chem. Soc. Jpn. 1978, 51, 2401-2404.
44. Hassner, A.; Alexanian, A. Direct Room Temperature of Carboxylic Acids. Tetrahedron Lett. 1978, 46, 4475-4478.
45. Wade, L. G.; Gerdes, J. M.; Wirth, R. P. Protection of Carboxylic Acids as Methylthiomethyl Esters. Tetrahedron Lett. 1978, 8, 731-732.
46. Hollinshead, S. P.; Nichols, J. B.; Wilson, J. W. Two Practical Syntheses of Sterically Congested Benzophenones. J. Org. Chem. 1994, 59, 6703-6709.
47. Charpentier, B.; Bernardon, J. M.; Eustache, J.; Millois, C.; Martin, B. Synthesis, Structure-Affinity Relationships, and Biological Activities of Ligands Binding to Retinoic Acid Receptor Subtypes. J. Med. Chem. 1995, 38, 4993-5006.